Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ILK-IN-2 is an inhibitor of integrin-linked kinase (ILK; IC50 = 0.6 µM).1 It inhibits the phosphorylation of Akt, glycogen synthase kinase 3β (GSK3β), and myosin light-chain (MLC) in PC3 prostate and MDA-MB-231 breast cancer cells when used at concentrations ranging from 1 to 4 µM. ILK-IN-2 inhibits the proliferation of LNCaP, PC3, MDA-MB-231, MDA-MB-468, SK-BR-3, and MCF-7 cancer cells (IC50s = 1.6, 2, 1, 1.5, 1.8, and 2.5 µM, respectively), as well as induces autophagy and apoptosis in PC3 cells when used at a concentration of 2 µM. It also reduces protein levels of Y-box binding protein (YB-1), HER2, and EGFR in PC3 cells. ILK-IN-2 (25 and 50 mg/kg) reduces tumor growth in a PC3 mouse xenograft model.
WARNING This product is not for human or veterinary use.
1. Identification and characterization of a novel integrin-